化疗相关再生障碍性贫血的体细胞与免疫特征分析
研究对24例化疗相关再生障碍性贫血(CAA)患者进行全外显子测序,并与未发生AA的肿瘤患者及原发性AA患者比较。CAA的体细胞变异谱显著不同:免疫异常程度高于non-AA肿瘤但轻于PAA,髓系演变倾向高于non-AA肿瘤,转化机制较PAA更复杂。
要点
- CAA患者HLA-DRB1变异频率高于non-AA肿瘤患者(FDR=0.029)。
- CAA患者BRCA2、ASXL1等198个基因变异频率高于non-AA肿瘤患者。
- CAA患者HLA-A、HLA-C变异频率低于PAA患者(FDR分别为0.082、0.058)。
核心结论
- CAA的体细胞变异谱与non-AA肿瘤及PAA显著不同,免疫异常程度介于两者之间,髓系演变倾向高于non-AA肿瘤但转化机制较PAA更复杂。
研究设计与样本
- 纳入2019年9月至2023年5月北京协和医院确诊的24例CAA患者(男女比3∶5,中位年龄60岁),采集外周血行全外显子测序,并与non-AA肿瘤及PAA公开数据比较。
主要发现
- 共检出37 111个变异,涉及9 958个基因,KEGG富集分析显示基因主要集中于JAK-STAT和钙离子信号通路(均P<0.01)。
- CAA患者HLA-DRB1变异频率高于non-AA肿瘤患者(FDR=0.029),HLA-A(FDR=0.082)和HLA-C(FDR=0.058)变异频率低于PAA患者。
- 与non-AA肿瘤患者相比,CAA患者BRCA2(FDR=0.032)、ASXL1(FDR=0.047)等198个基因变异频率更高,SAA2(FDR=0.049)、TP53(FDR=0.045)、PIK3CA(FDR=0.049)等基因变异频率更低。
- 与PAA患者相比,CAA患者BRCA2(FDR=0.068)、ATRX(FDR=0.072)等213个基因变异频率更高,ASXL1(FDR=0.045)、DNMT3A(FDR=0.078)等14个基因变异频率更低。
临床怎么用
- 对CAA患者可关注HLA-DRB1、BRCA2、ASXL1等基因变异,评估免疫异常及髓系演变风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aimed to characterize the somatic variant candidate gene profile of patients with chemotherapy-associated aplastic anemia (CAA) and compare it with that of patients with cancer without aplastic anemia (non-AA) and primary aplastic anemia (PAA). This study included 24 patients with CAA diagnosed at Peking Union Medical College Hospital from September 2019 to May 2023 (male-to-female ratio of 3∶5; median age, 60 years). Peripheral blood samples were collected for whole-exome sequencing, and the results were compared with publicly available data of patients with non-AA and PAA. A total of 37 111 variants across 9 958 genes were detected. KEGG enrichment analysis revealed that these genes were mainly concentrated in the JAK-STAT and calcium signaling pathways (all P<0.01). Regarding human leukocyte antigen (HLA) genes, the mutation frequency of HLA-DRB1 was higher in patients with CAA than in those with non-AA cancer [false discovery rate (FDR) =0.029], whereas the mutation frequencies of HLA-A (FDR=0.082) and HLA-C (FDR=0.058) were lower than in those with PAA. For myeloid disease-related genes, compared with patients with non-AA cancer, those with CAA had higher mutation frequencies in 198 genes, including BRCA2 (FDR=0.032) and ASXL1 (FDR=0.047), and lower frequencies in SAA2 (FDR=0.049), TP53 (FDR=0.045), and PIK3CA (FDR=0.049). Compared with patients with PAA, those with CAA had higher mutation frequencies in 213 genes, including BRCA2 (FDR=0.068) and ATRX (FDR=0.072), and lower frequencies in 14 genes, including ASXL1 (FDR=0.045) and DNMT3A (FDR=0.078). In conclusion, the somatic variant profile of CAA significantly differs from that of non AA cancer and PAA: its degree of immune abnormality is higher than that in non-AA cancer but milder than that in PAA; it shows a higher potential for myeloid evolution than non-AA cancer, but its transformation mechanism is more complex than that of PAA, being influenced by multiple factors including primary tumor characteristics and myeloid gene variants. 本研究旨在描述化疗相关性再生障碍性贫血(CAA)患者的体细胞变异候选基因谱,并与未发生AA(non-AA)的肿瘤患者及原发性AA(PAA)患者进行比较。研究纳入2019年9月至2023年5月在北京协和医院确诊的24例CAA患者(男女比3∶5,中位年龄60岁),采集外周血进行全外显子测序,将结果与non-AA肿瘤患者及PAA患者的公开数据进行对比分析。共检出37 111个变异,涉及9 958个基因,KEGG富集分析显示这些基因主要集中于JAK-STAT信号通路、钙离子信号通路等(均P<0.01)。在HLA基因方面,CAA患者的HLA-DRB1变异频率高于non-AA肿瘤患者(FDR=0.029),而HLA-A(FDR=0.082)和HLA-C(FDR=0.058)变异频率则低于PAA患者。在髓系疾病相关基因方面,与non-AA肿瘤患者相比,CAA患者中BRCA2(FDR=0.032)、ASXL1(FDR=0.047)等198个基因的变异频率更高,SAA2(FDR=0.049)、TP53(FDR=0.045)、PIK3CA(FDR=0.049)等基因的变异频率更低;与PAA患者相比,CAA患者中BRCA2(FDR=0.068)、ATRX(FDR=0.072)等213个基因变异频率更高,ASXL1(FDR=0.045)、DNMT3A(FDR=0.078)等14个基因变异频率更低。综上,CAA患者的体细胞变异谱与non-AA肿瘤患者及PAA患者存在显著差异:其免疫异常程度高于non-AA肿瘤患者但轻于PAA患者,髓系演变倾向较non-AA肿瘤患者更高,但转化机制较PAA患者更复杂,受原发肿瘤特性及髓系基因变异等多重因素影响。.
引用
- Zhang YM, Zhou YX, Zhuang QL, et al. [Somatic and immune profiling of chemotherapy-associated aplastic anemia: a comparison with primary aplastic anemia and cancer without aplastic anemia]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42409738. doi:10.3760/cma.j.cn121090-20251119-00539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。